Event Date/Time: Nov 30, 2004
End Date/Time: Dec 01, 2004
Governmental agencies and the ICH now recommend, and will soon require, in vitro non-clinical tests to screen all new drugs for their potential harmful effects to the cardiovascular system. Discuss the latest changes to cardiovascular drug safety and new findings in drug development. Take lessons learned from experienced industry leaders back to your company! Learn strategies for designing effective and compliant QT studies from Pfizer, Eli Lilly, Mayo Clinic, Duke University, AstraZeneca, Covance, Abbott, and more.